<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00692120</url>
  </required_header>
  <id_info>
    <org_study_id>2006-0013</org_study_id>
    <nct_id>NCT00692120</nct_id>
  </id_info>
  <brief_title>Clinical Approaches to Correcting Vitamin D Inadequacy and Maintaining Adequacy</brief_title>
  <acronym>D2/D3</acronym>
  <official_title>Clinical Approaches to Correcting Vitamin D Inadequacy and Maintaining Adequacy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitamin D is available in two forms, vitamin D2 and vitamin D3. It has previously been&#xD;
      assumed that these two forms maintain blood vitamin D equally. However, this may not be the&#xD;
      case. This study will evaluate whether D2 and D3 produce equal elevation of blood vitamin D.&#xD;
      Additionally, it will evaluate whether once per month vitamin D dosing is as effective in&#xD;
      maintaining blood vitamin D levels as daily dosing.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome measure is change in 25OHD with various D2 and D3 dosing regimens.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine whether once monthly vitamin D2 or D3 dosing is as effective as daily dosing in attainment, and subsequent maintenance, of 25OHD status</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delineate the effect of these vitamin D regimens on other parameters of skeletal relevance</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Vitamin D Inadequacy</condition>
  <condition>Vitamin D Deficiency</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Cholecalciferol (vitamin D3)</intervention_name>
    <description>50,000 IU once monthly for 12 months</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ergocalciferol (vitamin D2)</intervention_name>
    <description>oral capsule 50,000 IU once monthly for 12 months</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ergocalciferol (vitamin D2)</intervention_name>
    <description>oral capsule 1600 IU once daily for 12 months</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Cholecalciferol (vitamin D3)</intervention_name>
    <description>oral capsule 1600 IU once daily for 12 months</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral placebo capsule once daily for 12 months</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Community dwelling men and women age ≥ 65 years.&#xD;
&#xD;
          2. Able and willing to sign informed consent.&#xD;
&#xD;
          3. Serum 25OHD concentration ≥ 10 and less than 60 ng/ml by HPLC.&#xD;
&#xD;
          4. Willing to avoid use of cod-liver oil and non-study vitamin D supplementation;&#xD;
             standard multiple vitamins containing ≤ 400 IU used no more than once daily will be&#xD;
             allowed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current hypercalcemia (serum calcium &gt; 10.5 mg/dl) or untreated primary&#xD;
             hyperparathyroidism.&#xD;
&#xD;
          2. History of nephrolithiasis.&#xD;
&#xD;
          3. Screening 25OHD concentration ≥ 60 ng/ml.&#xD;
&#xD;
          4. Baseline 24-hour urine calcium &gt; 250 mg if female, &gt; 300 mg if male.&#xD;
&#xD;
          5. Known risk factors for hypercalcemia, e.g., malignancy, tuberculosis, sarcoidosis,&#xD;
             Paget's disease&#xD;
&#xD;
          6. History of any form of cancer within the past five years with the exception of&#xD;
             adequately treated squamous cell or basal cell skin cancer.&#xD;
&#xD;
          7. Renal failure defined as a calculated creatinine clearance (Cockroft-Gault method) ≤&#xD;
             25 ml/minute&#xD;
&#xD;
          8. Severe end-organ disease, e.g., cardiovascular, hepatic, hematologic, pulmonary, etc.,&#xD;
             which may limit ability to complete the study&#xD;
&#xD;
          9. Known malabsorption syndromes, e.g., celiac disease, radiation enteritis, active&#xD;
             inflammatory bowel disease, etc.&#xD;
&#xD;
         10. Use of medications known to alter bone turnover including bisphosphonates, estrogen,&#xD;
             selective estrogen receptor modulators, PTH, testosterone or calcitonin&#xD;
&#xD;
         11. Vitamin D intake greater than 5,000 IU daily&#xD;
&#xD;
         12. Treatment with any active metabolites of vitamin D within six months of screening&#xD;
&#xD;
         13. Treatment with any drug which may interfere with vitamin D metabolism, e.g.,&#xD;
             phenobarbital, phenytoin.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil Binkley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin - Institute on Aging</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UW Osteoporosis Clinical and Research Program</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <study_first_submitted>January 2, 2008</study_first_submitted>
  <study_first_submitted_qc>June 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2008</study_first_posted>
  <last_update_submitted>October 1, 2015</last_update_submitted>
  <last_update_submitted_qc>October 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

